TEVA’s TEV-408 shows favorable phase II-A celiac results
TEV-408, an anti-IL-15 antibody, demonstrated statistically and clinically meaningful gut-architecture protection and inflammation reduction in a phase II-A celiac disease study, with favorable safety and symptom trends. The program will advance to further regulatory discussions.